COLL · Collegium Pharmaceutical, Inc.
$35.20
+1.07% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$2B
Trailing P/E
17.2
Forward P/E
4.7
Dividend yield
—
Beta
0.73
Avg volume
0M
Employees
0K
2D change
—
5D change
-0.20%
10D change
-1.55%
30D change
-2.92%
60D change
5.68%
MTD change
-0.98%
YTD change
-23.28%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — COLL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-03-20
Latest call per bank · past 12 months
Barclays
Overweight$56.00
+59.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-03-20 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2026-03-19 | Needham | Reiterates | Buy | $54.00 → $56.00 |
| 2026-02-26 | Needham | Maintains | Buy | $56.00 → $54.00 |
| 2026-01-09 | Barclays | Maintains | Overweight | $58.00 → $56.00 |
| 2026-01-09 | HC Wainwright & Co. | Reiterates | Buy | $46.00 → $60.00 |
| 2026-01-08 | Needham | Maintains | Buy | $48.00 → $56.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $58.00 |
| 2025-11-07 | Truist Securities | Maintains | Buy | $45.00 → $48.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.6% above the 50-day MA ($34.66).
- Price vs 200-day MA: Trading 8.6% below the 200-day MA ($39.27).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($29.75) and high ($49.84).
COLL Price Chart
Loading chart for COLL…
Fundamentals
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.